AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The pharmaceutical market is currently defined by a race to replace aging blockbusters with next-generation therapies. Deciding whether to buy AbbVie Inc (NYSE:ABBV) or Eli Lilly and Co (NYSE:LLY) requires weighing different growth engines.

Both companies operate in the same general space but offer distinct profiles. AbbVie relies on its deep roots in immunology and neuroscience, while Eli Lilly is experiencing massive growth driven by its metabolic and obesity platform.

AbbVie is a giant among pharmaceutical stocks , focusing on immunology, oncology, and neuroscience therapies. Revenue is highly concentrated, with Skyrizi and Rinvoq making up roughly 42% of sales in 2025. To diversify, the company recently announced it would acquire Apogee Therapeutics (NASDAQ:APGE) for approximately $10.9 billion.

In FY 2025, revenue reached nearly $61.2 billion, reflecting growth of roughly 8.7% over the previous year. Net income for the period was close to $4.3 billion. This performance shows the ability to maintain top-line growth even as older products face competitive pressure.

As of its December 2025 balance sheet, the company reported a debt-to-equity ratio of negative 21x, meaning total liabilities exceed shareholder equity. The so-called current ratio, which measures the ability to pay short-term obligations, is approximately 0.7x. Free cash flow reached nearly $17.8 billion, providing substantial capital for dividends and further acquisitions.

Eli Lilly focuses its efforts on high-growth areas like diabetes, obesity, and oncology. Its GLP-1 drugs, Mounjaro and Zepbound, are major drivers, accounting for roughly 56% of total revenue in 2025. The company maintains collaborations with partners like Incyte Corp (NASDAQ:INCY) and recently entered a new agreement with OmniAb Inc (NASDAQ:OABI).

In FY 2025, revenue reached nearly $65.2 billion, which is a significant 45% increase compared to the prior year. Net income for the same period was approximately $20.6 billion. The sharp rise in both metrics highlights the rapid market adoption of its new metabolic therapies.

As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 1.6x. The current ratio is approximately 1.6x, indicating a solid position to meet short-term liabilities. Free cash flow for the year was close to $9.0 billion, which supports its ongoing research and development initiatives.

AbbVie faces significant pressure from patent expirations and the rise of biosimilar competition for its primary immunology drugs. Government-mandated price reductions through the Inflation Reduction Act also threaten revenue for key products like Vraylar and Botox. This concentration in a few major therapies makes the business vulnerable to any regulatory or safety shifts.